Literature DB >> 14638800

Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity.

Gilla Kaplan1, Frank A Post, Andre L Moreira, Helen Wainwright, Barry N Kreiswirth, Melike Tanverdi, Barun Mathema, Srinivas V Ramaswamy, Gabi Walther, Lafras M Steyn, Clifton E Barry, Linda-Gail Bekker.   

Abstract

Protective immunity against pulmonary tuberculosis (TB) is characterized by the formation in the lungs of granulomas consisting of macrophages and activated T cells producing tumor necrosis factor alpha and gamma interferon, both required for the activation of the phagocytes. In 90% of immunocompetent humans, this response controls the infection. To understand why immunity fails in the other 10%, we studied the lungs of six patients who underwent surgery for incurable TB. Histologic examination of different lung lesions revealed heterogeneous morphology and distribution of acid-fast bacilli; only at the surface of cavities, i.e., in granulomas with a patent connection to the airways, were there numerous bacilli. The mutation profile of the isolates suggested that a single founder strain of Mycobacterium tuberculosis may undergo genetic changes during treatment, leading to acquisition of additional drug resistance independently in discrete physical locales. Additional drug resistance was preferentially observed at the cavity surface. Cytokine gene expression revealed that failure to control the bacilli was not associated with a generalized suppression of cellular immunity, since cytokine mRNA was up regulated in all lesions tested. Rather, a selective absence of CD4(+) and CD8(+) T cells was noted at the luminal surface of the cavity, preventing direct T-cell-macrophage interactions at this site, probably allowing luminal phagocytes to remain permissive for bacillary growth. In contrast, in the perinecrotic zone of the granulomas, the two cell types colocalized and bacillary numbers were substantially lower, suggesting that in this microenvironment an efficient bacteriostatic or bactericidal phagocyte population was generated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638800      PMCID: PMC308931          DOI: 10.1128/IAI.71.12.7099-7108.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

2.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

3.  Local nerve damage in leprosy does not lead to an impaired cellular immune response or decreased wound healing in the skin.

Authors:  M Ruby Siddiqui; Andre L Moreira; Yohannes Negesse; Genet A Taye; Willem A Hanekom; Patrick A J Haslett; Sven Britton; Gilla Kaplan
Journal:  J Infect Dis       Date:  2002-07-03       Impact factor: 5.226

4.  A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes.

Authors:  P Anderson; C Nagler-Anderson; C O'Brien; H Levine; S Watkins; H S Slayter; M L Blue; S F Schlossman
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

5.  Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis.

Authors:  F Dieli; M Troye-Blomberg; J Ivanyi; J J Fournié; M Bonneville; M A Peyrat; G Sireci; A Salerno
Journal:  Eur J Immunol       Date:  2000-05       Impact factor: 5.532

6.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; D Hartel; V A Lewis; E E Schoenbaum; S H Vermund; R S Klein; A T Walker; G H Friedland
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

7.  Nosocomial epidemic of active tuberculosis among HIV-infected patients.

Authors:  G Di Perri; M Cruciani; M C Danzi; R Luzzati; G De Checchi; M Malena; S Pizzighella; R Mazzi; M Solbiati; E Concia
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

8.  Synchronized replication of Mycobacterium tuberculosis.

Authors:  L G Wayne
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

9.  TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection.

Authors:  Daniel R Roach; Andrew G D Bean; Caroline Demangel; Malcolm P France; Helen Briscoe; Warwick J Britton
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

10.  The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice.

Authors:  T Mogues; M E Goodrich; L Ryan; R LaCourse; R J North
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  152 in total

1.  Cytokine expression profiles of bovine lymph nodes: effects of Mycobacterium bovis infection and bacille Calmette-Guérin vaccination.

Authors:  S Widdison; L J Schreuder; B Villarreal-Ramos; C J Howard; M Watson; T J Coffey
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis.

Authors:  Russell R Kempker; Alexander S Rabin; Ketino Nikolaishvili; Iagor Kalandadze; Shota Gogishvili; Henry M Blumberg; Sergo Vashakidze
Journal:  Clin Infect Dis       Date:  2011-12-23       Impact factor: 9.079

3.  The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs.

Authors:  Lee G Klinkenberg; Jong-Hee Lee; William R Bishai; Petros C Karakousis
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

Review 4.  Surgical treatment of drug-resistant tuberculosis.

Authors:  Russell R Kempker; Sergo Vashakidze; Nelly Solomonia; Nino Dzidzikashvili; Henry M Blumberg
Journal:  Lancet Infect Dis       Date:  2012-02       Impact factor: 25.071

5.  Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  Richard Long; Richard Jones; James Talbot; Irvin Mayers; James Barrie; Michael Hoskinson; Bruce Light
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Replication dynamics of Mycobacterium tuberculosis in chronically infected mice.

Authors:  Ernesto J Muñoz-Elías; Juliano Timm; Tania Botha; Wai-Tsing Chan; James E Gomez; John D McKinney
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  Evaluation of the inaccurate assignment of mixed infections by Mycobacterium tuberculosis as exogenous reinfection and analysis of the potential role of bacterial factors in reinfection.

Authors:  Ana Martín; Marta Herranz; Yurena Navarro; Sandra Lasarte; María Jesús Ruiz Serrano; Emilio Bouza; Darío García de Viedma
Journal:  J Clin Microbiol       Date:  2011-02-23       Impact factor: 5.948

8.  Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction.

Authors:  Michael E Urbanowski; Elizabeth A Ihms; Kristina Bigelow; André Kübler; Paul T Elkington; William R Bishai
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

Review 9.  The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Borna Müller; Sonia Borrell; Graham Rose; Sebastien Gagneux
Journal:  Trends Genet       Date:  2012-12-13       Impact factor: 11.639

10.  Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates.

Authors:  Laura E Via; P Ling Lin; Sonja M Ray; Jose Carrillo; Shannon Sedberry Allen; Seok Yong Eum; Kimberly Taylor; Edwin Klein; Ujjini Manjunatha; Jacqueline Gonzales; Eun Gae Lee; Seung Kyu Park; James A Raleigh; Sang Nae Cho; David N McMurray; JoAnne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.